Advanced search×

Evidence strength in FDA premarket approval of cardiovascular devices.

David F Kong, Vic Hasselblad, and Mitchell W Krucoff

JAMA 303(16):1599-600; author reply 1600-1 (2010) PMID 20424248

DOI: 10.1001/jama.2010.511
Version: za2963e q8zac q8zb6 q8zcd q8zd9 q8ze8 q8zf2 q8zg6

Similar articles you may find interesting…

  1. Cardiac troponin T and creatine kinase predict mid-term infarct size and left ventricular function after acute myocardial infarction: A card...
    Agnes Mayr, Johannes Mair, ... Bernhard Metzler

    J Magn Reson Imaging 33(4):847-54 (2011) PMID 21448949

    To assess the relation of cardiac troponin T (cTnT) and creatine kinase (CK) release with infarct size and left ventricular function evaluated during the subacute phase as well as four months after acute myocardial infarction (AMI) by contrast-enhanced MRI (CE-MRI). C...
  2. Defining high-risk patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention: a c...
    Alessandro A Martinoni, Stefano S De Servi, ... Silvio S Klugman

    Int J Cardiol 157(2):207-11 (2012) PMID 21236505

    There is a large variability in risk stratification, sensitivity, specificity and predictive values among different scoring systems. These considerations should be taken into account when designing randomised trials. Copyright © 2010 Elsevier Ireland Ltd. All rights reserved....
  3. Angiotensin-II type 1 receptor and NOX2 mediate TCF/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophy.
    Prakashsrinivasan P Shanmugam, Anthony J AJ Valente, ... Bysani B Chandrasekar

    J Mol Cell Cardiol 50(6):928-38 (2011) PMID 21376054

    We investigated whether Ang-II-induced cardiomyocyte hypertrophy is dependent on WNT1 inducible signaling pathway protein 1 (WISP1), a pro growth factor. Ang-II induced hypertrophy and WISP1 expression in neonatal rat cardiomyocytes (NRCM), effects that were significantly inhibited by pre-treatment...
    View PDF